Enterprise Europe Network

New family of compounds targeting Alzheimer's disease

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20210602001
Published
02/06/2021
Last update
14/06/2021
Expiration date
15/06/2022

Keywords

Partner keyword: 
Neurology, Brain Research
Pharmaceutical Products / Drugs
Biochemistry / Biophysics
Anatomy, Pathology, Immunology, Physiology
EXPRESS YOUR INTEREST

Summary

Summary: 
A research team composed by researchers from three Spanish Universities has developed a new family of I2 Imidazoline Receptor ligands with anti-inflammatory and neuroprotective activity, opening a new therapeutic approach for Alzheimer's disease treatment. The compounds are characterized by presenting considerably fewer cardiovascular side-effects compared to existing ones. A pharmaceutical company interested in developing an Alzheimer's disease drug is being sought.

Description

Description: 

Alzheimer’s disease is the largest unmet medical need in neurology. Existing drugs have scarce or limited efficacy and no new cognitive enhancer drugs are available currently.

A new family of I2 Imidazoline Receptor ligands (compounds referred to as I2-IR ligands), selective against I2-IR and with potential less side-effects, has been developed by a research team composed by researchers from three Spanish Universities. The team has specialists in the area of synthesis of heterocyclic compounds with interest in the treatment of Alzheimer’s disease, neuropharmacology and neuropsychopharmacology.

The new family of synthetic compounds developed relates to the field of compounds with high affinity for imidazoline receptors of the I2-type, which have been associated with prevention or treatment of human brain disorders, such as depression and Alzheimer’s disease, pain modulation, and inflammation.

I2-IR are involved in physiologic processes related to analgesia, anti-inflammation and neuroprotection among others, which offers a wide range of applications for compounds targeting this type of proteins.

It is also known that in Alzheimer’s disease brain patients the density (Bmax) of I2 imidazoline binding sites is significantly higher than in control samples, and that I2-IR ligands have neuroprotectant properties. In this regard, other I2-IR ligands have been developed and tested, but most of them show cardiac side-effects due to their activity upon α2-adrenergic receptors (α2-AR).

Inspired in this rational, researchers focused their effort on developing compounds targeting selectively I2-IR; avoiding side-effects due to α2-AR activation and opening a new therapeutic approach for Alzheimer’s disease treatment.

However, given the nature of I2-IR, other indications may also be targeted, such as osteoarthritis pain.

Advantages & innovations

Cooperation plus value: 
Potentially less cardiovascular side-effects thanks to low affinity for α2-AR. New therapeutic approach for AD treatment with anti-inflammatory and neuroprotective activity.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
The partner sought could be a big pharma company engaged in the development of Alzheimer’s disease drugs and interested in: - A licence agreement to commercialise the technology. - A research cooperation agreement to co-develope a drug. - A financial agreement to move to the next clinical phases.

Type and size

Cooperation task: 
SME 11-50,>500 MNE,251-500,SME 51-250,>500